PSTI - プルリステム・セラピュ―ティクス (Pluristem Therapeutics Inc.) プルリステム・セラピュ―ティクス

 PSTIのチャート


 PSTIの企業情報

symbol PSTI
会社名 Pluristem Therapeutics Inc (プルリステム・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 プルリステム・セラピューティクス(Pluristem Therapeutics Inc.)は生物治療薬の会社であり、変性性、虚血性及び自己免疫性重症疾患の治療向けの非個別化(同種異系)細胞治療製品の商業化に従事する。同社は在庫既製のヒト胎盤由来製品のパイプラインを開発している。上記のヒト胎盤は非論争的な非胚性成体間質細胞の供給源である。胎盤由来の接着間質細胞(ASC)は、身体の自然微細構造を模倣する「PluriX」と言う同社の三次元(3-D)バイオリアクターで栽培される。同社は筋肉内投与経路の臨床適応症を中心としている。該当投与経路は末梢動脈疾患(PAD)、重症虚血肢(CLI)、間欠性跛行、神経因性疼痛、創傷治癒及び整形外科傷害を含む異なる適応症に応用できる。   プルリステム・セラピュ―ティクスは、イスラエルのバイオ医薬品企業。複数の虚血性および炎症治療のための同種細胞治療製品開を開発する。特許取得製品は、PLX(胎盤拡張)細胞。この製品は、三次元プロセスを使用する接着間質細胞で心血管、整形外科、肺及び女性健康などの病気に対応する臨床段階にある。本社はハフィア。   
本社所在地 MATAM Advanced Technology Park Building No.5 Haifa 31905 ISR
代表者氏名 Yaky Yanay ヤキヤネイ
代表者役職名 Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者
電話番号 +972 74-710-8600
設立年月日 37012
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 180人
url www.pluristem.com
nasdaq_url https://www.nasdaq.com/symbol/psti
adr_tso
EBITDA EBITDA(百万ドル) -31.71300
終値(lastsale) 1.22
時価総額(marketcap) 138586489.26
時価総額 時価総額(百万ドル) 136.31460
売上高 売上高(百万ドル) 0.05000
企業価値(EV) 企業価値(EV)(百万ドル) 106.41460
当期純利益 当期純利益(百万ドル) -26.12600
決算概要 決算概要 BRIEF: For the fiscal year ended 30 June 2018 Pluristem Therapeutics Inc. revenues increased from $0K to $50K. Net loss decreased 6% to $26.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects G/L on Invest. HFS Maturity_Trading increase from $513K (expense) to $8.5M (income) Research and development expenses - Bala decrease of 38% to $11.7M (expense).

 PSTIのテクニカル分析


 PSTIのニュース

   Mesenchymal Stem Cells Market Analysis By Main Players Pluristem Therapeutics, LonzaThermo, Fisher, ATCC, Bio-Techne, MilliporeSigma, Genlantis, Celprogen, Cell Applications, PromoCell GmbH,  2021/01/25 08:41:41 OpenPR
The “Mesenchymal Stem Cells Market” Research Report 2020-2027 is a specialized and in-depth study of the Mesenchymal Stem Cells industry with a focus on the global market trend. The report aims to provide an overview of global Mesenchymal Stem Cells
   Mesenchymal Stem Cells Market - Pluristem Therapeutics, LonzaThermo, Fisher, ATCC, Bio-Techne, MilliporeSigma, Genlantis, Celprogen, Cell Applications, PromoCell GmbH, Cyagen Biosciences, Human Longevity Inc.  2020/10/13 09:13:30 OpenPR
Global Mesenchymal Stem Cells Market Analysis, Size, Share, Outlook and Forecast to 2020-2027 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific). The market attractiveness
   Abu Dhabi Stem Cells Center und Pluristem präsentieren gemeinsame Projekte auf der Online-Veranstaltung der Malta Conferences Foundation  2020/10/01 14:38:00 Business Wire
BERLIN--(BUSINESS WIRE)--Am Mittwoch, 30. September 2020, haben das führende israelische Unternehmen für regenerative Medizin Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), das eine Plattform für neuartige biologische Produkte entwickelt, und das Abu Dhabi Stem Cells Center (ADSCC) ihre ersten gemeinsamen Projekte in einer Präsentation bei der Malta Conferences Foundation (MCF) vorgestellt, einer weltweiten Konferenz, die von der kENUP Foundation, Förderin forschungsbasierter Innovation
   Pluristem Up 6% In Pre-Market On German Clearance For Covid-19 Study  2020/08/10 12:44:13 Smarter Analyst
Shares in Pluristem Therapeutics (PSTI) rose 6% in Monday’s pre-market trading after Germany’s health regulatory agency, the Paul Ehrlich Institute (PEI), approved Pluristem’s … The post Pluristem Up 6% In Pre-Market On German Clearance For Covid-19 Study appeared first on Smarter Analyst .
   Agenus : B Riley FBR Virtual Infectious Disease Summit Transcript | MarketScreener  2020/08/07 12:22:49 MarketScreener
Below is an unedited transcript from the B. Riley FBR Infectious Disease Summit Part III with Agenus, Inc. Excision BioTherapeutics, and Pluristem Therapeutics hosted by Mayank Mamtani… | August 7, 2020
   Pluristem Up 6% In Pre-Market On German Clearance For Covid-19 Study  2020/08/10 12:44:13 Smarter Analyst
Shares in Pluristem Therapeutics (PSTI) rose 6% in Monday’s pre-market trading after Germany’s health regulatory agency, the Paul Ehrlich Institute (PEI), approved Pluristem’s … The post Pluristem Up 6% In Pre-Market On German Clearance For Covid-19 Study appeared first on Smarter Analyst .
   Agenus : B Riley FBR Virtual Infectious Disease Summit Transcript | MarketScreener  2020/08/07 12:22:49 MarketScreener
Below is an unedited transcript from the B. Riley FBR Infectious Disease Summit Part III with Agenus, Inc. Excision BioTherapeutics, and Pluristem Therapeutics hosted by Mayank Mamtani… | August 7, 2020
   Is Pluristem Therapeutics (PSTI) Outperforming Other Medical Stocks This Year?  2020/05/15 15:30:15 Zacks Investment Research
Is (PSTI) Outperforming Other Medical Stocks This Year?
   Pluristem Provides 28-Day Follow Up for Ventilator-Dependent COVID-19 Patients under Compassionate Use Program in Israel and U.S.  2020/05/14 12:00:00 GlobeNewswire
Update is provided in advance of the company’s recruitment of first patient for its phase II Covid-19 study
   The Daily Biotech Pulse: Ayala IPO, Pluristem Starts Phase 2 Trial Of COVID Treatment, European Nod For Takeda  2020/05/08 11:59:45 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 7) • Acceleron Pharma Inc (NASDAQ: XLRN ) • Bio-Rad Laboratories, Inc. (NYSE: BIO ) • BIO-TECHNE Corp (NASDAQ: TECH ) • Catalent Inc (NYSE: CTLT ) • Cytosorbents Corp (NASDAQ: CTSO ) • DexCom, Inc. (NASDAQ: DXCM ) • GENMAB A/S/S ADR (NASDAQ: GMAB ) • Immunomedics, Inc. (NASDAQ: IMMU ) • Immunovant Inc (NASDAQ: IMVT ) • Kala Pharmaceuticals Inc (NASDAQ: KALA ) • Masimo Corporation (NASDAQ: MASI ) • Meridian Bioscience, Inc. (NASDAQ: VIVO ) • Minerva Neurosciences Inc (NASDAQ: NERV ) • Natera Inc (NASDAQ: NTRA ) • ORIC Pharmaceuticals Inc (NASDAQ: ORIC ) • Phathom Pharmaceuticals Inc (NASDAQ: PHAT ) • Quidel Corporation (NASDAQ: QDEL ) • Repligen Corporation (NASDAQ: RGEN ) • Revolution Medicines Inc (NASDAQ: RVMD ) • Scpharmaceuticals Inc (NASDAQ: SCPH ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 7) • Apyx Medical Corp (NASDAQ: APYX ) • Biofrontera AG (NASDAQ: BFRA ) • Sonnet Biotherapeutics Holdings Inc (NASDAQ: SONN ) Stocks In Focus Pluristem Gets FDA Nod To Initiate Phase 2 Study Of PLX Cells In COVID-19 Pluristem Therapeutics Inc. (NASDAQ: PSTI ) said the FDA cleared its IND application …
   Pluristem Up 6% In Pre-Market On German Clearance For Covid-19 Study  2020/08/10 12:44:13 Smarter Analyst
Shares in Pluristem Therapeutics (PSTI) rose 6% in Monday’s pre-market trading after Germany’s health regulatory agency, the Paul Ehrlich Institute (PEI), approved Pluristem’s … The post Pluristem Up 6% In Pre-Market On German Clearance For Covid-19 Study appeared first on Smarter Analyst .
   Agenus : B Riley FBR Virtual Infectious Disease Summit Transcript | MarketScreener  2020/08/07 12:22:49 MarketScreener
Below is an unedited transcript from the B. Riley FBR Infectious Disease Summit Part III with Agenus, Inc. Excision BioTherapeutics, and Pluristem Therapeutics hosted by Mayank Mamtani… | August 7, 2020
   Is Pluristem Therapeutics (PSTI) Outperforming Other Medical Stocks This Year?  2020/05/15 15:30:15 Zacks Investment Research
Is (PSTI) Outperforming Other Medical Stocks This Year?
   Pluristem Provides 28-Day Follow Up for Ventilator-Dependent COVID-19 Patients under Compassionate Use Program in Israel and U.S.  2020/05/14 12:00:00 GlobeNewswire
Update is provided in advance of the company’s recruitment of first patient for its phase II Covid-19 study
   The Daily Biotech Pulse: Ayala IPO, Pluristem Starts Phase 2 Trial Of COVID Treatment, European Nod For Takeda  2020/05/08 11:59:45 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 7) • Acceleron Pharma Inc (NASDAQ: XLRN ) • Bio-Rad Laboratories, Inc. (NYSE: BIO ) • BIO-TECHNE Corp (NASDAQ: TECH ) • Catalent Inc (NYSE: CTLT ) • Cytosorbents Corp (NASDAQ: CTSO ) • DexCom, Inc. (NASDAQ: DXCM ) • GENMAB A/S/S ADR (NASDAQ: GMAB ) • Immunomedics, Inc. (NASDAQ: IMMU ) • Immunovant Inc (NASDAQ: IMVT ) • Kala Pharmaceuticals Inc (NASDAQ: KALA ) • Masimo Corporation (NASDAQ: MASI ) • Meridian Bioscience, Inc. (NASDAQ: VIVO ) • Minerva Neurosciences Inc (NASDAQ: NERV ) • Natera Inc (NASDAQ: NTRA ) • ORIC Pharmaceuticals Inc (NASDAQ: ORIC ) • Phathom Pharmaceuticals Inc (NASDAQ: PHAT ) • Quidel Corporation (NASDAQ: QDEL ) • Repligen Corporation (NASDAQ: RGEN ) • Revolution Medicines Inc (NASDAQ: RVMD ) • Scpharmaceuticals Inc (NASDAQ: SCPH ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 7) • Apyx Medical Corp (NASDAQ: APYX ) • Biofrontera AG (NASDAQ: BFRA ) • Sonnet Biotherapeutics Holdings Inc (NASDAQ: SONN ) Stocks In Focus Pluristem Gets FDA Nod To Initiate Phase 2 Study Of PLX Cells In COVID-19 Pluristem Therapeutics Inc. (NASDAQ: PSTI ) said the FDA cleared its IND application …

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 プルリステム・セラピュ―ティクス PSTI Pluristem Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)